Breckenridge announced the launch of Desvenlafaxine Succinate Extended-Release Tablets, the generic version of Pfizer‘s Pristiq.

Pristiq is indicated to treat major depressive disorder (MDD). Non-clinical studies have shown that desvenlafaxine succinate is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Its clinical efficacy is thought to be related to the potentiation of these neurotransmitters in the central nervous system.

Related Articles

Desvenlafaxine Succinate is available as 50mg and 100mg extended-release tablets. It will share 180-day exclusivity with other Abbreviated New Drug Application (ANDA) first filers.

For more information call (561) 443-3314 or visit